Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer
- Author:
Eduardo GARCÍA
1
;
Natalie AYOUB
;
Krishnansu S. TEWARI
Author Information
- Publication Type:Review Article
- From:Journal of Gynecologic Oncology 2024;35(1):e30-
- CountryRepublic of Korea
- Language:English
- Abstract: Cervical cancer continues to be a global threat affecting individuals in resource poor communities disproportionately. The treatment paradigm for this disease is ever evolving with recent innovations propelling oncologic outcomes to a new frontier offering survival benefits for patients struggling with locally advanced disease and metastatic/recurrent carcinoma. Immunologic checkpoint inhibitors and anti-body drug conjugates represent two novel drug classes that have demonstrable activity in this disease, particularly in the first-line and second-line treatment paradigm for recurrence. The tolerability of these novel medicines and associated durable responses underscore regulatory approval by the U.S. Food and Drug Administrations and their implementation in clinic.
